background image

Paid Clinical Trials Louisville

Discover 501 paid clinical trials in Louisville, Kentucky. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
FeaturedActive & Responsive

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

for
Moderately to Severely Active Ulcerative Colitis
Location: Louisville KY, New Albany IN, Cincinnati OH,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 16 - 70+

Code: NCT06588855

Phase3, Recruiting
FeaturedActive & Responsive

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

for
Moderately to Severely Active Crohns Disease
Location: Louisville KY, New Albany IN, Crestview Hills KY,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 16 - 70+

Code: NCT06819878

Phase3, Recruiting
FeaturedActive & Responsive

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

for
Influenza
Location: Bardstown KY, Dayton OH, Mishawaka IN,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 0 - 11

Code: NCT06094010

Phase3, Recruiting
Featured

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

for
Breast Cancer
Location: Louisville KY, Lexington KY, Nashville TN, Urbana IL,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06790693

Phase3, Recruiting
Featured

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

for
Moderately to Severely Active Crohns Disease
Location: Louisville KY, Beavercreek OH, Nashville TN,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 16 - 70+

Code: NCT06819891

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Featured

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

for
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis,
Location: New Albany IN, Louisville KY, Liberty Township OH,
Sponsor: 89bio, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06318169

Phase3, Recruiting
Featured

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

for
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis,
Location: New Albany IN, Louisville KY, Cincinnati OH,
Sponsor: 89bio, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06419374

Phase3, Recruiting
Featured

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

for
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer,
Location: Louisville KY, Lexington KY, Nashville TN,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06065748

Phase3, Recruiting
Active & Responsive

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

for
NASH - Nonalcoholic Steatohepatitis,
Location: Louisville KY, Indianapolis IN, Springboro OH,
Sponsor: Akero Therapeutics, Inc

Sex: All

Age: 18 - 70+

Code: NCT06528314

Phase3, Recruiting
Active & Responsive

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

for
NASH With Fibrosis, MASH With Fibrosis
Location: Louisville KY, Indianapolis IN, Springboro OH,
Sponsor: Akero Therapeutics, Inc

Sex: All

Age: 18 - 70+

Code: NCT06215716

Phase3, Recruiting